BR112022010251A2 - Derivados de benzilamida como inibidores do receptor i/alk5 do fator de transformação de crescimento beta - Google Patents

Derivados de benzilamida como inibidores do receptor i/alk5 do fator de transformação de crescimento beta

Info

Publication number
BR112022010251A2
BR112022010251A2 BR112022010251A BR112022010251A BR112022010251A2 BR 112022010251 A2 BR112022010251 A2 BR 112022010251A2 BR 112022010251 A BR112022010251 A BR 112022010251A BR 112022010251 A BR112022010251 A BR 112022010251A BR 112022010251 A2 BR112022010251 A2 BR 112022010251A2
Authority
BR
Brazil
Prior art keywords
alk5
growth factor
diseases
compounds
receptor
Prior art date
Application number
BR112022010251A
Other languages
English (en)
Portuguese (pt)
Inventor
BOSSER ARTAL Ramón
Pampín Casal Begoña
Castro Palomino Laria Julio
Original Assignee
Origo Biopharma S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Origo Biopharma S L filed Critical Origo Biopharma S L
Publication of BR112022010251A2 publication Critical patent/BR112022010251A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
BR112022010251A 2019-11-28 2020-11-27 Derivados de benzilamida como inibidores do receptor i/alk5 do fator de transformação de crescimento beta BR112022010251A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19383057 2019-11-28
PCT/EP2020/083566 WO2021105317A1 (en) 2019-11-28 2020-11-27 Benzylamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5

Publications (1)

Publication Number Publication Date
BR112022010251A2 true BR112022010251A2 (pt) 2022-09-06

Family

ID=68808255

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022010251A BR112022010251A2 (pt) 2019-11-28 2020-11-27 Derivados de benzilamida como inibidores do receptor i/alk5 do fator de transformação de crescimento beta

Country Status (15)

Country Link
US (2) US12297186B2 (cg-RX-API-DMAC7.html)
EP (1) EP4065572A1 (cg-RX-API-DMAC7.html)
JP (2) JP7808032B2 (cg-RX-API-DMAC7.html)
CN (1) CN114787145B (cg-RX-API-DMAC7.html)
AR (1) AR120578A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020394531B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022010251A2 (cg-RX-API-DMAC7.html)
CA (1) CA3160963A1 (cg-RX-API-DMAC7.html)
ES (1) ES3029608T1 (cg-RX-API-DMAC7.html)
IL (1) IL293388B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022005843A (cg-RX-API-DMAC7.html)
PH (1) PH12022551177A1 (cg-RX-API-DMAC7.html)
SA (1) SA522432749B1 (cg-RX-API-DMAC7.html)
WO (1) WO2021105317A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202205149B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3978487A1 (en) 2020-09-30 2022-04-06 Origo Biopharma, S.L. 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5
AU2025225502A1 (en) 2024-02-22 2026-07-30 Agomab Spain S.L.U. Crystalline phase forms of a benzylamide derivative
WO2026082960A1 (en) 2024-10-18 2026-04-23 Agomab Therapeutics Nv 1,5-naphtyridine and quinoline based inhibitors of alk5
WO2026082968A1 (en) 2024-10-18 2026-04-23 Agomab Therapeutics Nv Novel compounds
CN122036718A (zh) * 2026-01-30 2026-05-15 安炎达医药技术(广州)有限公司 一种alk5抑制剂及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3621540A1 (de) 1986-06-27 1988-01-07 Basf Ag Chinolinderivate, verfahren zu ihrer herstellung, diese enthaltende mikrobizide und ihre verwendung zur bekaempfung von bakterien und pilzen
ATE291020T1 (de) * 2001-02-02 2005-04-15 Smithkline Beecham Corp Pyrazolderivate gegen tgf überexprimierung
WO2004026306A2 (en) 2002-09-18 2004-04-01 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
WO2004026302A1 (en) * 2002-09-19 2004-04-01 Eli Lilly And Company Methods of inhibiting tgf beta with substituted pyrazoles
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
CN102056907B (zh) 2008-04-04 2014-12-31 武田药品工业株式会社 杂环衍生物及其用途
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
WO2011076725A1 (en) 2009-12-21 2011-06-30 Bayer Cropscience Ag Thienylpyri (mi) dinylazole and their use for controlling phytopathogenic fungi
RU2612958C2 (ru) * 2011-07-13 2017-03-14 Ск Кемикалз Ко., Лтд. 2-пиридилзамещенные имидазолы в качестве ингибиторов alk5 и/или alk4
US11021468B2 (en) * 2015-04-01 2021-06-01 Rigel Pharmaceuticals, Inc. TGF-ß inhibitors
WO2016172631A2 (en) 2015-04-24 2016-10-27 President And Fellows Of Harvard College Substrate selective inhibitors of insulin-degrading enzyme (ide) and uses thereof
KR102434226B1 (ko) * 2016-06-30 2022-08-19 한미약품 주식회사 Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도
JP2021518855A (ja) 2018-03-02 2021-08-05 ユニヴェルシテ ド ローザンヌ Wntシグナル伝達経路阻害剤としてのピラゾール誘導体
US11945803B2 (en) 2018-08-07 2024-04-02 Tosk, Inc. Modulators of RAS GTPase
CN110433164A (zh) * 2019-08-15 2019-11-12 南开大学 TGF-beta受体分子抑制剂在治疗小鼠动物模型中急性髓系白血病的应用
EP3978487A1 (en) 2020-09-30 2022-04-06 Origo Biopharma, S.L. 2-(3-pyridin-2-yl-4-quinolin-4-yl-pyrazol-1-yl)-acetamide derivatives as inhibitors of transforming growth factor-beta receptor i/alk5

Also Published As

Publication number Publication date
SA522432749B1 (ar) 2025-05-12
AU2020394531B2 (en) 2026-06-25
US12297186B2 (en) 2025-05-13
JP7808032B2 (ja) 2026-01-28
CN114787145B (zh) 2024-03-26
KR20220107180A (ko) 2022-08-02
WO2021105317A1 (en) 2021-06-03
IL293388B1 (en) 2025-12-01
EP4065572A1 (en) 2022-10-05
ES3029608T1 (en) 2025-06-24
IL293388B2 (en) 2026-04-01
US20250333395A1 (en) 2025-10-30
JP2025163046A (ja) 2025-10-28
AU2020394531A1 (en) 2022-06-09
AR120578A1 (es) 2022-02-23
US20230025933A1 (en) 2023-01-26
JP2023504795A (ja) 2023-02-07
PH12022551177A1 (en) 2024-02-05
ZA202205149B (en) 2025-06-25
MX2022005843A (es) 2022-07-19
IL293388A (en) 2022-07-01
CA3160963A1 (en) 2021-06-03
CN114787145A (zh) 2022-07-22

Similar Documents

Publication Publication Date Title
BR112021018664A2 (pt) Inibidores de proteína tirosina fosfatase
BR112015023948A2 (pt) composto de fórmula (i), composição farmacêutica, método para o tratamento e/ou prevenção de uma doença proliferativa e para a inibição ou a diferenciação do crescimento de uma célula tronco do câncer
ECSP23054131A (es) Cocristal de un inhibidor de cdk
BR112022010383A2 (pt) Compostos tricíclicos substituídos
TR201816176T4 (tr) Histon deasetilaz 6 inhibitörleri olarak yeni bileşikler ve bunu içeren farmasötik bileşimler.
BR112015014458A8 (pt) compostos derivados de manose, seus intermediários, composição, uso e processos de preparação
NO20090723L (no) Kondenserte heterosykliske derivater og fremgangsmater for anvendelse
BR112022024120A2 (pt) Derivado de piridina-pirimidina, método de preparação do mesmo e uso farmacêutico do mesmo
BR112015029972A2 (pt) composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, método para o tratamento de uma doença, conjunto e utilização de um composto
BR112012031727A2 (pt) conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença.
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112012021364A2 (pt) "compostos cicloalquila contendo tienopirimidinas e composições farmacêuticas".
BR112015020600A2 (pt) composição farmacêutica, método para o tratamento de e/ou melhorar doenças de gordura no fígado de origem não alcoólica e uso da composição
BR112014012129A8 (pt) inibidores heterocíclicos de glutaminase
BRPI0805826A2 (pt) compostos espiro-substituìdos como inibidores de angiogênese, método de produção de um composto, composição farmacêutica e métodos de tratamento
MX2013012588A (es) Inhibidores de cinasa.
BR112015016911A2 (pt) tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
BR112016015236A8 (pt) composto,composição farmacêutica,uso de um composto,método de inibição e método para tratar ou aliviar a gravidade de uma doença.
MX2022005843A (es) Derivados de bencilamida como inhibidores del receptor i del factor de crecimiento transformante beta/ cinasa similar al receptor de activina 5 (alk5).
BR112016028819A2 (pt) composição farmacêutica, métodos para tratar uma doença ou condição em um ser humano e para inibir a atividade de um polipeptídeo de fosfatidilinositol 3-quinase e reações imunológicas excessivas ou destrutivas ou o crescimento ou a proliferação de células cancerosas, kit, composto, sal farmaceuticamente aceitável, isômero ou mistura dos mesmos, e, uso de um composto, sal farmaceuticamente aceitável ou mistura dos mesmos.
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
BR112017025851A2 (pt) compostos de pirazol e pirrol substituídos e métodos para usar os mesmos para inibição de iniciação de tradução e tratamento de doenças e distúrbios relacionados aos mesmo
BR112014032581A2 (pt) inibidores de bifluorodioxalano-amino-benzimidazol qui-nase para o tratamento de câncer, distúrbios do snc e inflamação autoimune
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: AGOMAB SPAIN, S.L.U. (ES)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]